Flow cytometric analysis of Human CD86 expression on human peripheral blood cells. Human peripheral blood cells were stained with either Biotin Rabbit IgG Isotype Control (black line histogram) or SDT Biotin Rabbit Anti-Human CD86 Antibody (red line histogram) at 5 μl/test followed by Sav-iFluor 488. Flow cytometry and data analysis were performed using Agilent NovoCyte Quanteon and FlowJo™ software.
Biotin Rabbit Anti-Human CD86 Antibody (S-990-1)
Biotin Rabbit Anti-Human CD86 Antibody (S-990-1)
Price:
Regular price
$100 USD
Regular price
Sale price
$100 USD
Unit price
per
For shipping services or bulk orders, you may request a quotation.
Secure checkout with
View full details
Product Details
Product Details
Product Specification
| Host | Rabbit |
| Antigen | CD86 |
| Synonyms | T-lymphocyte activation antigen CD86; Activation B7-2 antigen; B70; BU63; CTLA-4 counter-receptor B7.2; FUN-1; CD28LG2 |
| Immunogen | Recombinant Protein |
| Location | Cell membrane |
| Accession | P42081 |
| Clone Number | S-990-1 |
| Antibody Type | Recombinant mAb |
| Isotype | IgG |
| Application | FCM |
| Reactivity | Hu |
| Positive Sample | Human Peripheral Blood cells |
| Purification | Protein A |
| Concentration | 0.2 mg/ml |
| Conjugation | Biotin |
| Physical Appearance | Liquid |
| Storage Buffer | PBS pH7.4, 0.09% sodium azide |
| Stability & Storage | 12 months from date of receipt / reconstitution, 2 to 8 °C as supplied |
Dilution
| application | dilution | species |
| FCM | 5μl per million cells in 100μl volume | Hu |
Background
CD86, also known as B7-2, is a co-stimulatory molecule expressed on the surface of antigen-presenting cells (APCs) such as dendritic cells, macrophages, and B cells. It plays a crucial role in the immune response by interacting with CD28 on T cells to provide a necessary co-stimulatory signal for T cell activation, proliferation, and differentiation. Additionally, CD86 can also bind to CTLA-4, an inhibitory receptor on T cells, thereby regulating immune responses and maintaining immune homeostasis. This dual functionality makes CD86 a key target in immunotherapy research, particularly in the development of cancer treatments and autoimmune disease management strategies.
Picture
Picture
FC
